The Human Variable 

CRISPR²™ (CRISPR Readiness Index, Stabilization, Personalized Recovery) introduces a state-dependent framework for gene editing in complex chronic disease. Unlike conventional models that assume biological stability, CRISPR² integrates patient readiness, environmental exposure, temporal symptom dynamics, and recovery conditions to guide when and how intervention occurs. This approach expands therapeutic reach across severity levels, improves interpretation of outcomes in vari

Stage Zero™ defines the preclinical phase where immune and autonomic instability is already active but not yet captured by traditional diagnostics. By identifying structured symptom patterns, timing-based responses, and multi-system disruption, this framework enables earlier recognition of disease activity across conditions such as Long COVID, ME/CFS, POTS, and autoimmune disorders. Rather than waiting for diagnostic thresholds, Stage Zero™ introduces a trajectory-based model

Remission is often defined as symptom improvement at a single moment in time. The CYNAERA Remission Standard™ challenges that assumption by introducing a state-dependent model that evaluates stability, durability, function, flare control, and resilience over time. Applied across Long COVID, autoimmune disease, and clinical trials, this framework provides a more accurate way to measure recovery, reduce misclassification, and align outcomes with real-world patient experience.

Why does IBD take months or years to diagnose? The failure is not missing symptoms. It is missing the pattern. CDF-IBD™ introduces a new framework for early detection of inflammatory bowel disease using pattern recognition, flare intelligence, and system-level correction. Designed to address IBS misdiagnosis, referral delays, and fragmented care, this model identifies IBD earlier, improves escalation, and reduces preventable disease progression.

POTS clinical trials often fail by treating a multi-system disorder as a narrow cardiovascular condition. This CYNAERA framework outlines stabilization, phenotype stratification, adaptive design, and real-world endpoints to improve outcomes and reduce trial failure.

Personalized CRISPR Remission™ for Long COVID introduces a state-dependent gene editing framework based on biological readiness, stabilization, and recovery to improve timing, safety, and durability in immune-volatile disease.

Why rheumatoid arthritis is often misdiagnosed or delayed. Learn early RA symptoms, diagnostic gaps, and how CDF-RA™ improves early detection.

A field guide for designing Lyme disease clinical trials that work. Learn how to improve outcomes using adaptive design, co-infection stratification, digital biomarkers, and CYNAERA’s stabilization-first framework.

The Target Readiness Index™ (TRI) introduces a state-dependent framework for CRISPR target prioritization across ME/CFS, Long COVID, Lyme disease, and autoimmune conditions including lupus, type 1 diabetes, Hashimoto’s, and Sjögren’s.

SymCas™ is a flare prediction model for POTS, Lyme disease, ME/CFS, Long COVID and relapsing chronic conditions. It identifies symptom patterns over time to detect early instability and support proactive care.

The true U.S. burden of Lyme disease is estimated at 5 - 7 million Americans, according to CYNAERA’s US-CCUC™ 2026 prevalence model, substantially higher than the roughly 400,000 to 500,000 diagnoses recorded annually. By accounting for underdiagnosis, chronic illness, and fragmented surveillance, this paper reframes Lyme disease as a major chronic illness burden rather than a narrowly counted regional infection.

Personalized CRISPR Remission™ for ME/CFS explores customized, individualized gene-editing strategies based on immune state, environmental factors, and neuroimmune instability to enable state-dependent remission in infection-associated chronic conditions. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex, multi-system condition. Personalized CRISPR Remission™ for MECFS is not limited to one editing event or one delivery paradigm.